Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Str. 3a, 06120 Halle, Germany.
Viruses. 2023 Jun 24;15(7):1431. doi: 10.3390/v15071431.
The oncofetal RNA-binding protein IGF2BP1 has been reported to be a driver of tumor progression in a multitude of cancer entities. Its main function is the stabilization of target transcripts by shielding these from miRNA-mediated degradation. However, there is growing evidence that several virus species recruit IGF2BP1 to promote their propagation. In particular, tumor-promoting viruses, such as hepatitis B/C and human papillomaviruses, benefit from IGF2BP1. Moreover, recent evidence suggests that non-oncogenic viruses, such as SARS-CoV-2, also take advantage of IGF2BP1. The only virus inhibited by IGF2BP1 reported to date is HIV-1. This review summarizes the current knowledge about the interactions between IGF2BP1 and different virus species. It further recapitulates several findings by presenting analyses from publicly available high-throughput datasets.
癌胚 RNA 结合蛋白 IGF2BP1 已被报道在多种癌症实体中是肿瘤进展的驱动因素。它的主要功能是通过屏蔽这些靶转录物免受 miRNA 介导的降解来稳定这些靶转录物。然而,越来越多的证据表明,几种病毒物种招募 IGF2BP1 来促进它们的繁殖。特别是促肿瘤病毒,如乙型肝炎/丙型肝炎病毒和人乳头瘤病毒,都受益于 IGF2BP1。此外,最近的证据表明,非致癌病毒,如 SARS-CoV-2,也利用 IGF2BP1。迄今为止,唯一被报道受到 IGF2BP1 抑制的病毒是 HIV-1。这篇综述总结了目前关于 IGF2BP1 与不同病毒物种之间相互作用的知识。它进一步通过呈现来自公开可用的高通量数据集的分析来概括了一些发现。